Preferred Label : Lorigerlimab;
NCIt synonyms : PD-1 x CTLA4 Bispecific DART Molecule MGD019; Dual-affinity Retargeting Protein MGD019; D-1 x CTLA4 DART Protein MGD019; Bispecific DART Protein MGD019; PD-1 x CTLA4 DART Protein MGD019; Anti-PD-1/Anti-CTLA4 DART Protein MGD019; MGD-019;
NCIt definition : A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein
directed against the human negative immunoregulatory checkpoint receptors programmed
cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen
4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic
activities. Upon administration, lorigerlimab specifically binds to both PD-1 and
CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and
CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade
of PD1 and CTLA4 pathways provides enhanced activity against PD1 CTLA4 double positive
cells and may increase T-cell activation and proliferation compared to the blockade
of either immune checkpoint alone.;
UNII : JM802R57SA;
CAS number : 2416595-46-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2416595-46-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : MGD 019; MGD019; AEX-1344;
NCI Metathesaurus CUI : CL938054;
Origin ID : C158505;
UMLS CUI : C5706648;
Semantic type(s)
- concept_is_in_subset
- has_target
